Semaglutide, the popular weight loss and diabetes drug, now has the green light to treat moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). If you have the condition and are ...

Related reads:Apple Creator Studio Suite Consisting of Creative Apps Such As Final Cut Pro, and More Announced; Price and Other Details Here Apple has revealed the most downloaded apps and games on ...

Apple has shared its list of the most downloaded apps and games on the App Store for 2025. The annual report highlights user trends across iPhone and iPad, including free and paid apps as well as ...

Sareena was a senior editor for CNET covering the mobile beat, including device reviews. She is a seasoned multimedia journalist with more than a decade's worth of experience producing stories for ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an ...

How 'bout them apples? Michigan's lush and plentiful apple season is getting underway. And what's unique about Michigan apples is the wide variety with different flavor profiles available, from sweet ...

Cinemark shares popped Friday as the nation’s third-largest theater chain saw sales and profit jump in a June quarter that “launched out of the gate” with A Minecraft Movie followed by “a steady ...

To help get you primed and ready for another week in mobile gaming, we’ve curated the biggest stories you need to know from the last seven days. 1) Apple to launch dedicated gaming app across all ...